Please assess the completion status of the following clinical trial:

Trial Title: Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
* At increased risk of developing breast cancer, due to at least one of the following risk factors:~  * Gail score ≥ 1.66~ * Age ≥ 60 years~ * Prior atypical ductal hyperplasia, lobular hyperplasia, or lobular carcinoma in situ on breast biopsy~ * Prior ductal carcinoma in situ (DCIS) treated with total mastectomy with or without tamoxifen (tamoxifen must have been completed ≥ 3 months prior to randomization)~* No prior DCIS treated with lumpectomy with or without radiation~* No prior invasive breast cancer~* Not BRCA1 or BRCA2 carriers~PATIENT CHARACTERISTICS:~Previous:~* 35 and over~* Female~* Postmenopausal, defined as one of the following:~  * over 50 years of age with no spontaneous menses for at least 12 months before study entry~ * 50 years of age or under with no menses (spontaneous or secondary to hysterectomy) for at least 12 months before study entry AND with follicle-stimulating hormone level within postmenopausal range~ * Underwent prior bilateral oophorectomy~* No other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumors with no evidence of disease for ≥ 5 years~* No uncontrolled hypothyroidism or hyperthyroidism~* No major medical or psychiatric illness (including substance and alcohol abuse within the past 2 years) that would preclude study participation or compliance~* Must be accessible for treatment and follow-up~* Willing to complete quality of life questionnaires in either English or French~Current: MAP.3 participants who were randomized to the exemestane arm, are currently receiving exemestane as part of the MAP.3 study and who have not completed 5 years of exemestane.~OR MAP.3 study participants who were randomized to the placebo arm and who have either completed 5 years of study drug or who are still receiving placebo. Note: this applies only to centres that choose to allow placebo cross-over.~PRIOR CONCURRENT THERAPY:~Previous:~* More than 3 months since prior and no concurrent hormone replacement therapies~* More than 3 months since systemic estrogenic, androgenic, or progestational agents~* More than 3 months since prior and no concurrent hormonal therapies, including, but not limited to the following:~  * Luteinizing-hormone releasing-hormone analogs (e.g., goserelin or leuprolide)~ * Progestogens (e.g., megestrol)~ * Prolactin inhibitors (e.g., bromocriptine)~ * Antiandrogens (e.g., cyproterone acetate)~ * Selective estrogen-receptor modulators (e.g., tamoxifen, toremifene, or raloxifene)~* No investigational drug within 30 days or 5 half lives prior to randomization~* No concurrent endocrine therapy~* No concurrent estrogens, androgens, or progesterones~* Concurrent low dose (≤ 100 mg/day) prophylactic aspirin allowed~* Concurrent bisphosphonates for prevention or treatment of osteoporosis allowed~* No other concurrent medications that may have an effect on study endpoints~Current: There are no prior concurrent therapy restrictions for the amended MAP.3 study.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Exemestane (Type: OTHER): one 25 mg tablet daily in am

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete